# POU3F4

## Overview
POU3F4 is a gene that encodes the POU class 3 homeobox 4 protein, a transcription factor belonging to the POU family, which is characterized by a bipartite DNA-binding domain. This protein plays a pivotal role in the development of the inner ear and neural tissues, influencing the transcription of target genes that are crucial for cellular differentiation and development. The POU3F4 protein is primarily active in the nucleus and is involved in the regulation of gene expression during specific developmental phases, particularly in the brain and inner ear. It interacts with various proteins and nucleic acids, forming homo- and heterodimers with other transcription factors to enhance its target recognition and binding flexibility. Mutations in the POU3F4 gene are linked to X-linked nonsyndromic hearing loss, highlighting its clinical significance in auditory development and function (Bernardinelli2023Clinical; Coate2012Otic).

## Structure
The POU3F4 protein is a transcription factor belonging to the POU family, characterized by a bipartite DNA-binding domain. This domain consists of a POU-specific domain (POU S) and a C-terminal homeodomain (POU H), which are crucial for its function. The POU S domain is composed of 76-78 amino acids, forming a compact bundle of four helices with a helix-turn-helix conformation in the middle, while the POU H domain is 60 amino acids long and features a helix-turn-helix motif that interacts with DNA through a third helix (Bernardinelli2023Clinical). These domains are separated by a variable-length segment, providing structural flexibility for diverse DNA binding conformations (Bernardinelli2023Clinical).

The POU3F4 protein also contains three nuclear localization signals (NLSs), which are essential for its nuclear localization. Two NLSs are located within the POU H domain, specifically between amino acids G276 to T283 and N328 to R335, while the third NLS is within the POU S domain, spanning amino acids F201 to L208 (Bernardinelli2023Clinical). POU3F4 can form homo- and heterodimers with other POU family members or Sox family transcription factors, enhancing its target recognition and binding flexibility (Bernardinelli2023Clinical). Variants affecting these NLSs can disrupt protein trafficking and localization, leading to functional defects (Bernardinelli2023Clinical).

## Function
The POU3F4 gene encodes a transcription factor that plays a critical role in the development of the inner ear and neural tissues. It is part of the POU-domain family, characterized by a bipartite DNA-binding domain that allows for diverse DNA binding conformations, enabling it to regulate gene expression during development (Bernardinelli2023Clinical). POU3F4 is primarily active in the nucleus, where it influences the transcription of target genes, impacting cellular differentiation and development (Brooks2020Pou3f4‐expressing).

In the inner ear, POU3F4 is crucial for the development of the otic mesenchyme, which is essential for the proper formation of spiral ganglion neurons (SGNs) and their axon fasciculation. It regulates the expression of Epha4, a receptor involved in axon guidance, establishing an Eph/ephrin-mediated signaling pathway critical for auditory function (Coate2012Otic). POU3F4 also plays a role in the morphogenesis of the stapedial ossicle and the fasciculation of spiral ganglion neurons, which are essential for forming cochlear synapses and surrounding sensory hair cells (Bernardinelli2023Clinical).

The gene's expression is spatially and temporally limited, suggesting a specific role during certain developmental phases, particularly in the brain and inner ear (Bernardinelli2023Clinical).

## Clinical Significance
Mutations in the POU3F4 gene are associated with X-linked nonsyndromic hearing loss, specifically DFNX2, which is the most common form of X-linked deafness. This condition is characterized by mixed hearing loss, which can be conductive, sensorineural, or both, and is often progressive. Inner ear malformations, such as an incomplete partition of the cochlea type 3 (IP3) and enlarged vestibular aqueducts (EVA), are frequently observed in affected individuals (Pollak2016Novel; Bernardinelli2022Novel).

Mutations in POU3F4 can lead to a null function of the protein, disrupting its role as a transcription factor crucial for normal auditory development. These mutations often result in truncated proteins that lack DNA-binding domains, impairing transcriptional activity and leading to hearing loss (Chao2020Cochlear; Lee2009Clinical). The mutations can also cause mislocalization of the protein, affecting its subcellular distribution and further compromising its function (Parzefall2013Cytoplasmic).

The clinical manifestations of POU3F4 mutations include temporal bone abnormalities, stapes fixation, and vestibular dysfunction. These anatomical anomalies can complicate surgical interventions, such as cochlear implantation, due to the risk of cerebrospinal fluid leakage and potential meningitis (Pollak2016Novel).

## Interactions
POU3F4 is a transcription factor that interacts with various proteins and nucleic acids to regulate gene expression, particularly in the context of inner ear and neural development. It is known to bind to specific DNA sequences, such as the octamer binding motif 5' ATGCAAAT 3', which allows it to autoregulate its own transcription by binding to its promoter region (Bernardinelli2023Clinical). POU3F4 can form homo- and heterodimers with other POU family members or with transcription factors from the Sox family, which influences target recognition and increases binding flexibility (Bernardinelli2023Clinical).

In the inner ear, POU3F4 interacts with EphA4, a receptor tyrosine kinase, which is crucial for the fasciculation of spiral ganglion neurons (Bernardinelli2023Clinical). It also shows a common expression pattern with Ephrin-B2 during ear development, indicating its role in the development of bony tissue surrounding the vestibular labyrinth (Bernardinelli2023Clinical). Additionally, POU3F4 has been shown to upregulate the amino acid transporter SLC6A20 in cells overexpressing the transcription factor, highlighting its role in regulating gene expression (Bernardinelli2023Clinical). These interactions are essential for the proper development and function of auditory structures.


## References


[1. (Brooks2020Pou3f4‐expressing) Paige M. Brooks, Kevin P. Rose, Meaghan L. MacRae, Katherine M. Rangoussis, Mansa Gurjar, Ronna Hertzano, and Thomas M. Coate. Pou3f4‐expressing otic mesenchyme cells promote spiral ganglion neuron survival in the postnatal mouse cochlea. Journal of Comparative Neurology, 528(12):1967–1985, February 2020. URL: http://dx.doi.org/10.1002/cne.24867, doi:10.1002/cne.24867. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cne.24867)

[2. (Parzefall2013Cytoplasmic) Thomas Parzefall, Shaked Shivatzki, Danielle R. Lenz, Birgit Rathkolb, Kathy Ushakov, Daphne Karfunkel, Yisgav Shapira, Michael Wolf, Manuela Mohr, Eckhard Wolf, Sibylle Sabrautzki, Martin Hrabé de Angelis, Moshe Frydman, Zippora Brownstein, and Karen B. Avraham. Cytoplasmic mislocalization of pou3f4 due to novel mutations leads to deafness in humans and mice. Human Mutation, 34(8):1102–1110, May 2013. URL: http://dx.doi.org/10.1002/humu.22339, doi:10.1002/humu.22339. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22339)

[3. (Chao2020Cochlear) Xiuhua Chao, Yun Xiao, Fengguo Zhang, Jianfen Luo, Ruijie Wang, Wenwen Liu, Haibo Wang, and Lei Xu. Cochlear implantation in a patient with a novel pou3f4 mutation and incomplete partition type-iii malformation. Neural Plasticity, 2020:1–9, September 2020. URL: http://dx.doi.org/10.1155/2020/8829587, doi:10.1155/2020/8829587. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1155/2020/8829587)

[4. (Pollak2016Novel) Agnieszka Pollak, Urszula Lechowicz, Anna Kędra, Piotr Stawiński, Małgorzata Rydzanicz, Mariusz Furmanek, Małgorzata Brzozowska, Maciej Mrówka, Henryk Skarżyński, Piotr H. Skarżyński, Monika Ołdak, and Rafał Płoski. Novel and de novo mutations extend association of pou3f4 with distinct clinical and radiological phenotype of hearing loss. PLOS ONE, 11(12):e0166618, December 2016. URL: http://dx.doi.org/10.1371/journal.pone.0166618, doi:10.1371/journal.pone.0166618. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0166618)

[5. (Coate2012Otic) Thomas M. Coate, Steven Raft, Xiumei Zhao, Aimee K. Ryan, E. Bryan Crenshaw, and Matthew W. Kelley. Otic mesenchyme cells regulate spiral ganglion axon fasciculation through a pou3f4/epha4 signaling pathway. Neuron, 73(1):49–63, January 2012. URL: http://dx.doi.org/10.1016/j.neuron.2011.10.029, doi:10.1016/j.neuron.2011.10.029. This article has 83 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuron.2011.10.029)

[6. (Lee2009Clinical) Hee Keun Lee, Mee Hyun Song, Myengmo Kang, Jung Tae Lee, Kyoung-Ah Kong, Su-Jin Choi, Kyu Yup Lee, Hanka Venselaar, Gert Vriend, Won-Sang Lee, Hong-Joon Park, Taeg Kyu Kwon, Jinwoong Bok, and Un-Kyung Kim. Clinical and molecular characterizations of novelpou3f4mutations reveal that dfn3 is due to null function of pou3f4 protein. Physiological Genomics, 39(3):195–201, November 2009. URL: http://dx.doi.org/10.1152/physiolgenomics.00100.2009, doi:10.1152/physiolgenomics.00100.2009. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1152/physiolgenomics.00100.2009)

[7. (Bernardinelli2022Novel) Emanuele Bernardinelli, Sebastian Roesch, Edi Simoni, Angela Marino, Gerd Rasp, Laura Astolfi, Antonio Sarikas, and Silvia Dossena. Novel pou3f4 variants identified in patients with inner ear malformations exhibit aberrant cellular distribution and lack of slc6a20 transcriptional upregulation. Frontiers in Molecular Neuroscience, September 2022. URL: http://dx.doi.org/10.3389/fnmol.2022.999833, doi:10.3389/fnmol.2022.999833. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2022.999833)

[8. (Bernardinelli2023Clinical) Emanuele Bernardinelli, Florian Huber, Sebastian Roesch, and Silvia Dossena. Clinical and molecular aspects associated with defects in the transcription factor pou3f4: a review. Biomedicines, 11(6):1695, June 2023. URL: http://dx.doi.org/10.3390/biomedicines11061695, doi:10.3390/biomedicines11061695. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biomedicines11061695)